These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 18447597)

  • 1. New tubulin targeting agents currently in clinical development.
    Carlson RO
    Expert Opin Investig Drugs; 2008 May; 17(5):707-22. PubMed ID: 18447597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
    Tangutur AD; Kumar D; Krishna KV; Kantevari S
    Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
    Cortes J; Baselga J
    Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tubulin inhibitors: a patent review.
    Liu YM; Chen HL; Lee HY; Liou JP
    Expert Opin Ther Pat; 2014 Jan; 24(1):69-88. PubMed ID: 24313741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
    Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microtubules: a dynamic target in cancer therapy.
    Pasquier E; Kavallaris M
    IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting microtubule targeting agents: α-Tubulin and the pironetin binding site as unexplored targets for cancer therapeutics.
    Coulup SK; Georg GI
    Bioorg Med Chem Lett; 2019 Aug; 29(15):1865-1873. PubMed ID: 31130264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrrolotetrazinones deazaanalogues of temozolomide induce apoptosis in Jurkat cell line: involvement of tubulin polymerization inhibition.
    Viola G; Cecconet L; Leszl A; Basso G; Brun P; Salvador A; Dall'Acqua F; Diana P; Barraja P; Cirrincione G
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1235-51. PubMed ID: 19363609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a Series of Acridinones as Mechanism-Based Tubulin Assembly Inhibitors with Anticancer Activity.
    Magalhaes LG; Marques FB; da Fonseca MB; Rogério KR; Graebin CS; Andricopulo AD
    PLoS One; 2016; 11(8):e0160842. PubMed ID: 27508497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of novel derivatives of stilbene and macrocyclic compounds as potent of anti-microtubule factors.
    Borys F; Tobiasz P; Poterała M; Krawczyk H
    Biomed Pharmacother; 2021 Jan; 133():110973. PubMed ID: 33378993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
    Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
    Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tubulin: an example of targeted chemotherapy.
    Seligmann J; Twelves C
    Future Med Chem; 2013 Mar; 5(3):339-52. PubMed ID: 23464522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sterically induced conformational restriction: Discovery and preclinical evaluation of novel pyrrolo[3,2-d]pyrimidines as microtubule targeting agents.
    Pavana RK; Shah K; Gentile T; Dybdal-Hargreaves NF; Risinger AL; Mooberry SL; Hamel E; Gangjee A
    Bioorg Med Chem; 2018 Nov; 26(20):5470-5478. PubMed ID: 30297118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
    Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
    Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progress in the study of tubulin inhibitors].
    Shang H; Pan L; Yang S; Chen H; Cheng MS
    Yao Xue Xue Bao; 2010 Sep; 45(9):1078-88. PubMed ID: 21351562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
    Perez EA
    Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
    Zhu C; Zuo Y; Wang R; Liang B; Yue X; Wen G; Shang N; Huang L; Chen Y; Du J; Bu X
    J Med Chem; 2014 Aug; 57(15):6364-82. PubMed ID: 25061803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, biological evaluation, and 3D-QSAR analysis of podophyllotoxin-dioxazole combination as tubulin targeting anticancer agents.
    Wang ZZ; Sun WX; Wang X; Zhang YH; Qiu HY; Qi JL; Pang YJ; Lu GH; Wang XM; Yu FG; Yang YH
    Chem Biol Drug Des; 2017 Aug; 90(2):236-243. PubMed ID: 28079286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.